Phase 2 Study Evaluating the Safety and Efficacy of Eloxatin (Oxaliplatin) and Docetaxel as First-Line Therapy of Stage IV or IIIB Unresectable Non-Small Cell Lung Cancer

Trial Profile

Phase 2 Study Evaluating the Safety and Efficacy of Eloxatin (Oxaliplatin) and Docetaxel as First-Line Therapy of Stage IV or IIIB Unresectable Non-Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Docetaxel (Primary) ; Oxaliplatin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jul 2007 The expected completion date for this trial is now 1 Dec 2007.
    • 05 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top